Literature DB >> 12682568

Inhalational anthrax and bioterrorism.

Richard Quintiliani1, Richard Quintiliani1.   

Abstract

Until recently, inhalational anthrax was considered an infectious disease curiosity for medical specialists and veterinarians. This attitude abruptly changed following the intentional release of Bacillus anthracis spores via the US Postal Service in October 2001. Because of its rarity, few physicians were familiar with its clinical manifestations, treatment and prophylaxis. In this report, we try to fill this informational gap by reviewing these issues based on additional data culled from this recent bioterrorism-related epidemic. Moreover, we have purposely emphasized its clinical manifestations, searching for common findings that may alert the physician to suspect and rapidly diagnose this infection. To improve survival rates, prompt diagnosis of inhalational anthrax is crucial, since even a brief delay in therapy of this fulminating infection almost uniformly results in death.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12682568     DOI: 10.1097/00063198-200305000-00011

Source DB:  PubMed          Journal:  Curr Opin Pulm Med        ISSN: 1070-5287            Impact factor:   3.155


  8 in total

Review 1.  Exposing a killer: pathologists angle for anthrax.

Authors:  Stephen W Chensue
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

Review 2.  Pyroptotic cell death defends against intracellular pathogens.

Authors:  Ine Jorgensen; Edward A Miao
Journal:  Immunol Rev       Date:  2015-05       Impact factor: 12.988

3.  The Reach of Patient Simulation: Is There No Boundary?

Authors:  Gary E Loyd
Journal:  J Educ Perioper Med       Date:  2004-01-01

4.  Investigation of antimicrobial and protease-inhibitory activity from cultured cyanobacteria.

Authors:  George Chlipala; Shunyan Mo; Esperanza J Carcache de Blanco; Aiko Ito; Stanley Bazarek; Jimmy Orjala
Journal:  Pharm Biol       Date:  2009-01       Impact factor: 3.503

5.  NLRP1-dependent pyroptosis leads to acute lung injury and morbidity in mice.

Authors:  Martina Kovarova; Pamela R Hesker; Leigh Jania; MyTrang Nguyen; John N Snouwaert; Zhidan Xiang; Stephen E Lommatzsch; Max T Huang; Jenny P-Y Ting; Beverly H Koller
Journal:  J Immunol       Date:  2012-06-29       Impact factor: 5.422

Review 6.  Binary bacterial toxins: biochemistry, biology, and applications of common Clostridium and Bacillus proteins.

Authors:  Holger Barth; Klaus Aktories; Michel R Popoff; Bradley G Stiles
Journal:  Microbiol Mol Biol Rev       Date:  2004-09       Impact factor: 11.056

7.  Bacillus anthracis cell wall produces injurious inflammation but paradoxically decreases the lethality of anthrax lethal toxin in a rat model.

Authors:  Xizhong Cui; Junwu Su; Yan Li; Joseph Shiloach; Steven Solomon; Jeanne B Kaufman; Haresh Mani; Yvonne Fitz; Jia Weng; Laith Altaweel; Virginia Besch; Peter Q Eichacker
Journal:  Intensive Care Med       Date:  2009-09-15       Impact factor: 17.440

8.  Bacillus anthracis cell wall peptidoglycan but not lethal or edema toxins produces changes consistent with disseminated intravascular coagulation in a rat model.

Authors:  Ping Qiu; Yan Li; Joseph Shiloach; Xizhong Cui; Junfeng Sun; Loc Trinh; Joanna Kubler-Kielb; Evgeny Vinogradov; Haresh Mani; Mariam Al-Hamad; Yvonne Fitz; Peter Q Eichacker
Journal:  J Infect Dis       Date:  2013-06-03       Impact factor: 5.226

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.